UPCOMING EVENTS
NEWS
The Washington Post – Synthetic Blood Substitute Research Advances Rapidly
One of KaloCyte’s co-founders, Dr. Allan Doctor, was among several experts interviewed for and quoted in the article on synthetic blood research, and KaloCyte’s ErythroMer and developmental status is featured
BioGenerator Highlights KaloCyte Case Study
BioGenerator leveraged its Grants, Fundamentals, and Grants- 2-Business programs enabling KaloCyte to craft and implement three highly innovative strategies (technical differentiation, accelerating regulatory path, Federal de-risking grants) to attract expertise and funding.
KaloCyte in the News: UMB Startups Receive Support from Maryland Momentum Fund
The University System of Maryland (USM) continues to aid entrepreneurs at UMB and throughout the state, including KaloCyte, with the $10 million Maryland Momentum Fund (MMF).
KaloCyte in the News: Old Line Capital Invests in KaloCyte
Old Line Capital Partners has made a significant investment in KaloCyte, Inc., to extend the research and development of break-through human blood substitute ErythroMer.
KaloCyte in the News: KaloCyte raises $300K from Maryland Momentum Fund
Months after moving to Baltimore, the company is growing its team and gaining funding from local institutions.
Press Release: KaloCyte, Inc., selected for Springboard’s Health Innovation Hub, Joins Network of more than 800 Seasoned Entrepreneurs
Elaine Haynes, president and CEO of KaloCyte, will join more than 800 experienced “been there, run that” entrepreneurs who make up the Springboard Expert Network.
Press Release: NIH Awards KaloCyte $373K SBIR Grant to Advance Synthetic Blood Product
The NIH SBIR grant will help KaloCyte develop ErythroMer™ to preclinical safety and efficacy testing.
ErythroMer in the News: Making and storing blood to save lives
KaloCyte co-founders Allan Doctor and Dipanjan Pan are featured in an article titled, “Making and storing blood to save lives”
Press Release: KaloCyte Welcomes Lyophilization Expert to its Baltimore Headquarters
KaloCyte welcomes Product Development Scientist, Nivesh Mittal, PhD to propel production of ErythroMer™
Maryland Booms in the BioCapital Hotbed
Elaine E. Haynes, President and CEO of KaloCyte, Inc., featured in BioSpace article touting Maryland, a BioCapital hotbed.
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by nearly $20M in federal grants and investor funding.